Vivos Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2025. The company generated revenues of $26,748, a substantial increase from $4,500 in the same period last year. Despite this growth in revenue, Vivos Inc. incurred a net loss of $834,696, compared to a net loss of $558,539 in the first quarter of 2024. The increase in losses can be attributed to higher operating expenses, which rose to $854,449 from $575,629 year-over-year, primarily due to increased professional fees, research and development costs, and general administrative expenses.
The company's total assets as of March 31, 2025, amounted to $3,301,867, up from $2,233,456 at the end of 2024. This increase was driven by a rise in cash reserves, which grew to $3,265,100 from $2,212,548. However, Vivos Inc. also saw its current liabilities increase to $115,378 from $86,209, reflecting a growing operational scale. The company's stockholders' equity rose to $3,186,489, compared to $2,147,247 at the end of the previous fiscal year, indicating a strengthening financial position despite ongoing losses.
Strategically, Vivos Inc. has focused on expanding its product offerings and market reach. The company is actively pursuing human clinical trials for its RadioGel™ product in India, having completed several regulatory and logistical requirements. Additionally, Vivos has begun charging clinics for certification to administer IsoPet® therapies, marking a shift in its revenue model. The company has also engaged Akina, Inc. to explore new business opportunities related to its hydrogel technology, which could diversify its revenue streams.
Operationally, Vivos Inc. has made strides in its customer engagement, with a notable increase in the number of certified clinics for its IsoPet® therapies. The company reported that it has begun ordering hydrogel for multiple treatments, which is expected to enhance its operational capacity. As of March 31, 2025, Vivos had 453,412,228 shares of common stock outstanding, reflecting its ongoing capital-raising efforts through Regulation A+ offerings, which have provided essential funding for its operations.
Looking ahead, Vivos Inc. anticipates requiring approximately $9 million in additional capital over the next 36 months to support its FDA approval processes, clinical trials, and expansion of its IsoPet® services. The company has expressed substantial doubt regarding its ability to continue as a going concern without securing further financing. Management remains focused on leveraging its existing technologies and partnerships to drive growth and improve its financial stability in the competitive oncology market.
About VIVOS INC
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.